方盛制药子公司中药创新药研发项目获得药物临床试验批准通知书

Group 1 - The core point of the article is that Fangsheng Pharmaceutical (603998.SH) announced that its subsidiary, Guangdong Fangsheng Runkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of its innovative traditional Chinese medicine, Ziying Granules [1] - The product is developed based on years of clinical experience in treating pelvic inflammatory disease and is aimed at alleviating chronic pelvic pain as a sequela of pelvic inflammatory disease [1] - The symptoms targeted by the treatment include lower abdominal pain, lumbar and sacral discomfort, increased vaginal discharge with yellow and thick characteristics, fluctuating low fever, aggravated abdominal pain during menstruation, chest tightness, poor appetite, dry mouth, loose stools or constipation, and yellowish urine [1]